BIVI
Biovie Inc.
$1.95
-0.23 (-10.55%)
At close · Jul 2
Market Cap
$14.71M
Shares
7,541,839
Price & Indicators
Indicators
Price
Panels
Event markers
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$1.95
Open$2.22
Day$1.95–2.23
52W$1.06–10.30
Avg vol 30d160K
Short int300K · 4.0% float · 2.5d
Short vol25%
DataSep 2020–Jul 2026
Filing10-Q · May 11
Equibles Rating
blended score · not investment advice
Overall
Buy
Technical · trend & momentum
Buy
◦
50 / 200-day cross
no cross
+
Price vs 200-day avg
+29% above
+
Price vs 50-day avg
+20% above
◦
RSI (14)
57 · neutral
+
MACD trend
positive
−
52-week position
10% · near low
Sentiment · smart money
Bearish
◦
Trend (MA cross)
50d $2 › 200d $2 — 50d above 200d
−
Institutional flow
-3% holders QoQ · +7 funds added
◦
Insider flow
No net insider activity over 90 days
−
Short interest
3.98% of float · ▲ +59.3% MoM · 2.5 days cover
◦
Volume signal
Volume near normal
+
Institution breadth
34 holders — near 1-yr high, broad support
Fundamentals
Excellent
+
EPS growth
+83% Y/Y
+
Balance sheet
net cash $17.5M
Blended from price, positioning & fundamentals · daily-close · not investment advice.
Up next
FQ1-27 quarter ends
~Sep 30, 2026
Est
filed May 11, 2026
Technicals
trend & momentum for long-term holders Buy
50 / 200-day cross
no cross
Neutral
Price vs 200-day avg
+29% above
Bullish
Price vs 50-day avg
+20% above
Bullish
RSI (14)
57 · neutral
Neutral
MACD trend
positive
Bullish
52-week position
10% · near low
Bearish
Market signals — smart money & positioning
Bearish · 2 of 6
Trend (MA cross)
No cross
50d $2 › 200d $2 — 50d above 200d
Institutional flow
Distributing
-3% holders QoQ · +7 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
3.98% of float · ▲ +59.3% MoM · 2.5 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
34 holders — near 1-yr high, broad support
Price context
position in its 52-week range
52-wk low $1
Now $2 · 10%
52-wk high $10
vs 200-day avg +29%
vs 50-day avg +20%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
BIVI
this stock
Biovie Inc.
|
$14.71M | +68.1% | — | — | 4.0% |
|
AKTX
Akari Therapeutics Plc
|
$953.21B | -9.9% | — | — | 0.0% |
|
ONC
BeOne Medicines Ltd.
|
$470.30B | -2.0% | +22179.2% | 957.1 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$134.02B | +16.5% | +46.2% | 31.3 | 1.8% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$69.80B | -15.1% | +20.8% | 16.3 | 3.2% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| BIVI | +9.6% | +18.2% | +50.0% | +0.5% | +68.1% |
| SPY | +1.4% | -1.3% | +8.0% | -0.3% | +9.2% |
| vs SPY | +8.1% | +19.4% | +42.0% | +0.8% | +58.9% |